 CAMBRIDGE, Mass., Nov. 10, 2021 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19. Both conferences will be held virtually. 